Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis

article

Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1080/13506129.2017.1292240
P698PubMed publication ID28434298

P50authorGiovanni PalladiniQ37839091
Giampaolo MerliniQ37839101
Paolo MilaniQ44254925
Stefan SchönlandQ47114671
Stefano PerliniQ57005375
Tilmann BochtlerQ92866574
P2093author name stringFrancesca Russo
Anthony D Ho
Andrea Foli
Ute Hegenbart
Christoph Kimmich
Marco Basset
P2860cites workBendamustine: rebirth of an old drugQ34947495
A practical approach to the diagnosis of systemic amyloidoses.Q41505050
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomesQ44572498
Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue.Q50526227
What is new in diagnosis and management of light chain amyloidosis?Q50863530
Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients.Q54337852
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosisQ58029845
P433issuesup1
P921main subjectbendamustineQ425745
AL amyloidosisQ4652470
P304page(s)56-57
P577publication date2017-03-01
P1433published inAmyloidQ4749545
P1476titleResponse to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis
P478volume24

Reverse relations

cites work (P2860)
Q47313576AL amyloidosis: from molecular mechanisms to targeted therapies
Q38600436Attitudes about when and how to treat patients with AL amyloidosis: an international survey.
Q47561519New concepts in the treatment and diagnosis of amyloidosis